Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients

Should we use Extracorporeal Photopheresis more often? Evidence from Graft-Versus-Host Disease Patients Monitored with Treg as a Biomarker

“…Despite the long-time clinical experience treating cGvHD patients with ECP, dating back to 1993 with apparent benefit, this technique is still not considered as a therapeutic option by some centers [ 17–19 ]. Available data relies mostly on small case series, with few clinical trials directly comparing ECP to other alternatives [ 11 , 20–22 ]. Although response rates vary among studies, improvement of symptoms are generally reported, always associated with an extremely low incidence of adverse reactions.…”

Pathogen‐inactivated blood products for pediatric patients: blood safety, patient safety, or both?

“…Despite regular clinical use, a 2015 Cochrane review confirmed that there are no randomized controlled trials in pediatric patients assessing its efficacy and harmful effects. Therefore, current understanding is based only on retrospective and observational studies . Known contraindications to ECP and 8‐methoxysalen exposure include aphakia, systemic lupus erythromatosus, and photosensitivity diseases (e.g., porphyria, xeroderma pigmentosum, albinism).…”